| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
23005 |
| Drug |
Burosumab |
| Brand |
Crysvita® |
| Indication |
Burosumab (Crysvita®) is indicated for X-linked hypophosphataemia in adult patients. |
| Rapid review commissioned |
03/02/2023 |
| Rapid review completed |
14/03/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of burosumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
28/03/2023 |
| Pre-submission consultation with Applicant |
13/06/2023 |
| Full submission received from Applicant |
19/09/2023 |
| Preliminary review sent to Applicant |
06/03/2024 |
| NCPE assessment re-commenced |
05/04/2024 |
| Follow-up to preliminary review sent to Applicant |
18/04/2024 |
| NCPE assessment re-commenced |
24/04/2024 |
